ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

Two Phase II Trials Display Ramucirumab Potential Efficacy

October 26, 2012

DCBD Board Okays Concept Of Program Announcement To Stimulate Human Monoclonal Antibody Research

June 4, 1982

Bayh To Receive ACCC Annual Award

February 8, 1980

In Brief: Cancer Act Renewal Nears, Appropriations Bills Lag; Interim Funding Likely For ’83 Fiscal Year

September 24, 1982

FDA Plans Safety Reviews Of Newly Approved Drugs; Drug Safety Bills Introduced In Senate.

February 2, 2007

Roswell Park Instigators Find Improved Treatment For Bladder Cancer

May 23, 1975